Letters |

Outcomes of a Trial of HIV-1 Immunogen in Patients With HIV Infection

Frances M. Gotch, PhD; Nesrina Imami, MD, PhD
JAMA. 2001;285(17):2191-2195. doi:10.1001/jama.285.17.2191.
Text Size: A A A
Published online


To the Editor: We believe that the HIV-1 Immunogen in the study by Dr Kahn and colleagues1 should be regarded at this point in time somewhat like zidovudine. It should not be forgotten that when zidovudine was first used as monotherapy, it diminished viral load but had no effect on the eventual clinical outcome2; however it paved the way for highly active ART. We have unpublished data showing that HIV-1 Immunogen is immunogenic (which supports the limited data given by Kahn et al); however, as with all other immunomodulatory therapy so far attempted, responses induced by immunotherapy in individuals infected with HIV are only transient and appear to have no effect on final clinical outcome. Thus, the important questions are how to induce long-term HIV-specific responses and how to reverse the anergy that causes many clinical problems in individuals with HIV. Recent data from treatment interruption studies after early treatment of primary HIV infection,3 immune control in long-term nonprogressors,4 and protection from infection that has been demonstrated in groups of exposed seronegative individuals5 raise hope that it will someday be possible to provide responses that are able to control viremia in individuals with chronic HIV.


Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview




Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 1

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.